Literature DB >> 8392210

Investigation of putative cardiac beta 3-adrenoceptors in man.

N M Wheeldon1, D G McDevitt, B J Lipworth.   

Abstract

The purpose of the present study was to investigate the presence of putative cardiac beta 3-adrenoceptors mediating chronotropic and inotropic responses in normal subjects. Isoprenaline (a known beta 1, beta 2 and beta 3-agonist) was infused to stimulate cardiac beta-adrenoceptors in the presence of antagonists at beta 1 (atenolol 25 mg) and beta 1/beta 2 (nadolol 5 mg, 20 mg and 80 mg) adrenoceptor subtypes. Dose-ranging with nadolol was performed to evaluate the lowest dose required to produce significant beta 2-blockade, since the higher doses might conceivably cause beta 3-blockade. Doppler echocardiography was used to evaluate stroke distance and minute distance, which are the linear analogues of stroke volume and cardiac output respectively. Nadolol 5 mg produced almost complete blunting of finger tremor (beta 2-blockade) whilst atenolol 25 mg had no significant effect. Chronotropic and Doppler minute distance responses to isoprenaline were consistent with stimulation of both beta 1 and beta 2-adrenoceptors with no evidence of a beta 3-mediated effect. However, isoprenaline produced an increase in systolic blood pressure and left ventricular stroke distance that was not attenuated by a dose of nadolol (20 mg) which produced complete blunting of beta 1 and beta 2-mediated responses. This infers the possibility of functional inotropic or lusitropic beta 3-adrenoceptors in the human heart. This study also brings into question possible differences in the validity of using stroke distance and systolic blood pressure as measures of inotropic response to beta-adrenoceptor stimulation and advocates the use of Doppler echocardiography as an additional tool for this purpose.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392210

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  8 in total

1.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

2.  Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

3.  Functional beta3-adrenoceptor in the human heart.

Authors:  C Gauthier; G Tavernier; F Charpentier; D Langin; H Le Marec
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 4.  Adrenaline, cardiac arrest, and evidence based medicine.

Authors:  T H Rainer; C E Robertson
Journal:  J Accid Emerg Med       Date:  1996-07

5.  The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

6.  Beta-adrenoceptor subtypes mediating the airways response to BRL 35135 in man.

Authors:  D M Newnham; C G Ingram; A Mackie; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

7.  Alterations of beta3-adrenoceptors expression and their myocardial functional effects in physiological model of chronic exercise-induced cardiac hypertrophy.

Authors:  J Barbier; F Rannou-Bekono; J Marchais; S Tanguy; F Carré
Journal:  Mol Cell Biochem       Date:  2006-11-28       Impact factor: 3.842

8.  β(3)-Adrenoceptor Antagonist SR59230A Attenuates the Imbalance of Systemic and Myocardial Oxygen Transport Induced by Dopamine in Newborn Lambs.

Authors:  Richdeep S Gill; Po-Yin Cheung; Xiaoyang Yu; Mohammed Al Aklabi; Jeevan Nagendran; Luis G Quinonez; Ying Qian Li; John Miller; David B Ross; Ivan M Rebeyka; Jia Li
Journal:  Clin Med Insights Cardiol       Date:  2012-02-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.